

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated.

Technology appraisals 90
ICB commissioned 17
Non-ICB commissioned 56
Not applicable 18
ICB commissioned and approved 17 (100%)
Average days to compliance 46

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [TA963]	Recommended	03/04/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma [TA964]	Recommended	10/04/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) [TA966]	Terminated appraisal	24/04/2024	TA					N/A	Terminated appraisal
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) [TA968]	Terminated appraisal	25/04/2024	TA					N/A	Terminated appraisal
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) [TA969]	Terminated appraisal	30/04/2024	TA					N/A	Terminated appraisal
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over [TA967]	Recommended	01/05/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 [TA971]	Recommended	08/05/2024	TA (EAMS)	07/06/2024	ICB	25/06/2024	48	These technologies are commissioned by integrated care boards. Providers are NHS hospital trusts	Red statement for remdesivir. Black RAG for tixagevimab plus cilgavimab
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments [TA970]	Recommended	08/05/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under [TA975]	Recommended	15/05/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma [TA972]	Recommended	15/05/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Atogepant for preventing migraine [TA973]	Recommended	15/05/2024	TA	13/08/2024	ICB	18/07/2024	64	This technology is commissioned by ICBs. Providers are secondary care acute hospital trusts (headache clinic) or primary care GP.	Amber retained statement
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia [TA298]	Recommended	20/05/2024	TA (Update)		ICB			TA update. The wording of the recommendation describing the patient access scheme has been updated to include procurement information about ranibizumab biosimilars.	Red RAG rating

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration [TA155]	Recommended	20/05/2024	TA (Update)		ICB			TA update. The wording of the recommendation describing the patient access scheme has been updated to include procurement information about ranibizumab biosimilars.	Red RAG rating
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion [TA283]	Recommended	20/05/2024	TA (Update)		ICB			TA update. The wording of the recommendation describing the patient access scheme has been updated to include procurement information about ranibizumab biosimilars.	Red RAG rating
Cladribine for treating relapsing–remitting multiple sclerosis [TA616]	Recommended	21/05/2024	TA		Non-ICB			TA update. The wording in has been updated to address concerns raised by the clinical community and company that the previously used definition of rapidly evolving severe multiple sclerosis (RES) was overly restrictive. This is because the requirement for 2 MRI scans places significant burden on a limited diagnostic and monitoring resource. The wording has now been changed to better reflect clinical practice.	NHS England
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis [TA312]	Recommended	21/05/2024	TA		Non-ICB			TA update. The wording in has been updated to address concerns raised by the clinical community and company that the previously used definition of rapidly evolving severe multiple sclerosis (RES) was overly restrictive. This is because the requirement for 2 MRI scans places significant burden on a limited diagnostic and monitoring resource. The wording has now been changed to better reflect clinical practice.	NHS England
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis [TA127]	Recommended	21/05/2024	TA		Non-ICB			TA update. The wording in has been updated to address concerns raised by the clinical community and company that the previously used definition of rapidly evolving severe multiple sclerosis (RES) was overly restrictive. This is because the requirement for 2 MRI scans places significant burden on a limited diagnostic and monitoring resource. The wording has now been changed to better reflect clinical practice.	NHS England
Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) [TA972]	Terminated appraisal	22/05/2024	TA					NICE is unable to make a recommendation because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.	Terminated appraisal
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) [TA978]	Terminated appraisal	29/05/2024	TA					NICE is unable to make a recommendation because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.	Terminated appraisal
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over [TA977]	Recommended	29/05/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) [TA976]	Terminated appraisal	29/05/2024	TA					NICE is unable to make a recommendation because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.	Terminated appraisal

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal) [TA980]	Terminated appraisal	05/06/2024	TA					NICE is unable to make a recommendation because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.	Terminated appraisal
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [TA979]	Recommended	05/06/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma [TA983]	Not recommended	12/06/2024	TA					N/A	Not recommended
Voxelotor for treating haemolytic anaemia caused by sickle cell disease [TA981]	Recommended	12/06/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) [TA982]	Terminated appraisal	13/06/2024	TA					N/A	Terminated appraisal
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [TA984]	Recommended	19/06/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Selective internal radiation therapies for treating hepatocellular carcinoma [TA688]	Recommended	03/07/2024	TA		Non-ICB			The technologies are commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma [TA985]	Recommended	03/07/2024	TA		Non-ICB			The technologies are commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal)	Terminated appraisal	10/07/2024	TA					N/A	Terminated appraisal
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [TA986]	Recommended	10/07/2024	TA	08/10/2024	ICB	15/08/2024	36	This technology is commissioned by NHS England for children and ICBs for adults. Providers are NHS hospital trusts.	Red RAG rating
Tenecteplase for treating acute ischaemic stroke [TA990]	Recommended	24/07/2024	TA (Cost comparison)	23/08/2024	ICB	15/08/2024	22	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG rating
Etranacogene dezaparovec for treating moderately severe or severe haemophilia B [TA989]	Recommended	24/07/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [TA988]	Recommended	24/07/2024	TA		Non-ICB			These technologies are commissioned by NHS England. Providers are NHS hospital trusts.	NHS England

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [TA992]	Not recommended	29/07/2024	TA					N/A	Not recommended
Abaloparatide for treating osteoporosis after menopause [TA991]	Recommended	07/08/2024	TA	05/11/2024	ICB	19/09/2024	43	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG rating
Burosumab for treating X-linked hypophosphataemia in adults [TA993]	Recommended	07/08/2024	TA		Non-ICB			These technologies are commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) [TA994]	Terminated appraisal	08/08/2024	TA					NICE is unable to make a recommendation because the company did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.	N/A
Linzagolix for treating moderate to severe symptoms of uterine fibroids [TA996]	Recommended	14/08/2024	TA	12/11/2024	ICB	18/10/2024	65	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts and primary care providers.	Amber initiated statement
Relugolix for treating hormone-sensitive prostate cancer [TA995]	Recommended	14/08/2024	TA	12/11/2024	ICB	17/10/2024	64	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts and primary care providers.	Amber retained statement
Risankizumab for treating moderately to severely active ulcerative colitis	Recommended	22/08/2024	TA (Cost comparison)	21/09/2024	ICB	19/09/2024	28	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG rating
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer [TA737]	Recommended	29/08/2024	TA (Update)		Non-ICB			TA update. This guidance was partially updated by NICE technology appraisal guidance 997 on pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma.	NHS England
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma [TA997]	Recommended	29/08/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Vibegron for treating symptoms of overactive bladder syndrome [TA999]	Recommended	04/09/2024	TA	03/12/2024	ICB	17/10/2024	43	This technology is commissioned by integrated care boards. Providers are Primary care and NHS hospital trusts.	Green statement
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment [TA1001]	Recommended	04/09/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Iptacopan for treating paroxysmal nocturnal haemoglobinuria [TA1000]	Recommended	04/09/2024	TA		Non-ICB			This technology is commissioned by NHS England.	NHS England
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [TA1005]	Recommended	11/09/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion [TA1004]	Recommended	11/09/2024	TA (Cost comparison)	11/10/2024	ICB	17/10/2024	36	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG rating
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over [TA1003]	Recommended	11/09/2024	TA		Non-ICB			This technology is commissioned by NHS England.	NHS England
Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over [TA1002]	Recommended	11/09/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS tertiary centres.	NHS England
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) [TA1006]	Terminated appraisal	12/09/2024	TA					N/A	Terminated appraisal
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer [TA1007]	Recommended	17/09/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [TA1008]	Recommended	25/09/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension [TA1009]	Recommended	02/10/2024	TA	31/12/2024	ICB	21/11/2024	50	Providers are NHS hospital trusts and primary care providers.	Amber recommended RAG rating
Belzutifan for treating tumours associated with von Hippel-Lindau disease [TA1011]	Recommended	16/10/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia [TA1013]	Recommended	23/10/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria [TA1010]	Recommended	23/10/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Avapritinib for treating advanced systemic mastocytosis [TA1012]	Recommended	06/11/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [TA1015]	Recommended	13/11/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [TA1014]	Recommended	13/11/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Elafibranor for previously treated primary biliary cholangitis	Recommended	14/11/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over	Recommended	20/11/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis	Recommended	20/11/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer	Recommended	20/11/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Eplontersen for treating hereditary transthyretin-related amyloidosis	Recommended	27/11/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Bevacizumab gamma for treating wet age-related macular degeneration [TA1022]	Recommended	04/12/2024	TA (Cost comparison)	03/01/2025	ICB	16/01/2025	43	This technology is commissioned by Integrated Care Boards Providers are NHS hospital trusts.	Red RAG rating
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer [TA1021]	Recommended	04/12/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal)	Terminated appraisal	11/12/2024	TA					N/A	Terminated appraisal
Eltanetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [TA1023]	Recommended	11/12/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Ublituximab for treating relapsing multiple sclerosis [TA1025]	Recommended	18/12/2024	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Tirzepatide for managing overweight and obesity [TA1026]	Recommended	23/12/2024	TA	23/03/2025	ICB	20/02/2025	59	90 day implemetation period for the initial funding variation cohort for use in specialist weight management settings (deadline 23/03/2025). 180 day implementation period for use in non-specialist settings (deadline 21/06/2025).	Red RAG rating for use in specialist services during initial 3 month implementation period
Tebentafusp for treating advanced uveal melanoma [TA1027]	Recommended	09/01/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban [TA697]	Recommended	15/01/2025	TA (Update)		ICB			TA update. Recommendation 1.2 was updated and replaced by NICE's technology appraisal guidance on andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage.	Red RAG rating

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [TA1030]	Recommended	15/01/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal) [TA1029]	Terminated appraisal	15/01/2025	TA					N/A	Terminated appraisal
Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal) [TA1028]	Terminated appraisal	15/01/2025	TA					N/A	Terminated appraisal
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over [TA1031]	Recommended	16/01/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours [TA1034]	Recommended	22/01/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal) [TA1032]	Terminated appraisal	22/01/2025	TA					N/A	Terminated appraisal
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [TA1035]	Recommended	23/01/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [TA1036]	Recommended	05/02/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [TA1037]	Recommended	05/02/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy [TA1040]	Recommended	12/02/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over [TA1039]	Recommended	12/02/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over [TA1038]	Recommended	12/02/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [TA1033]	Not recommended	12/02/2025	TA					N/A	Not recommended
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer [TA1042]	Recommended	19/02/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer [TA1041]	Recommended	19/02/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over [TA1044]	Recommended	26/02/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts (authorised providers).	NHS England
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [TA1043]	Recommended	26/02/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England